Hanneke O. Elberink

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

Journal: The Journal of allergy and clinical immunology
Published: December 16, 2025

Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

Journal: The journal of allergy and clinical immunology. In practice
Published: August 12, 2025

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Journal: NEJM evidence
Published: February 06, 2024

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.

Journal: Blood advances
Published: June 09, 2022

Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.

Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.

Journal: The journal of allergy and clinical immunology. In practice
Published: May 10, 2022

Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond.

Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond.

Journal: The journal of allergy and clinical immunology. In practice
Published: March 11, 2022

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.

Journal: The journal of allergy and clinical immunology. In practice
Published: February 21, 2022

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

Journal: HemaSphere
Published: August 03, 2021

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).

Journal: The journal of allergy and clinical immunology. In practice
Published: March 02, 2021

Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Journal: The Journal of allergy and clinical immunology
Published: January 15, 2021

Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin.

Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin.

Journal: The journal of allergy and clinical immunology. In practice
Published: July 13, 2020

Intradermal Tests With Drugs: An Approach to Standardization.

Intradermal Tests With Drugs: An Approach to Standardization.

Journal: Frontiers in medicine
Published: December 20, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026